{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T05:51:18Z","timestamp":1717221078518},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2011,1,18]],"date-time":"2011-01-18T00:00:00Z","timestamp":1295308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s11010-011-0730-8","type":"journal-article","created":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T10:05:30Z","timestamp":1295258730000},"page":"233-241","source":"Crossref","is-referenced-by-count":9,"title":["A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells"],"prefix":"10.1007","volume":"351","author":[{"given":"Xingchen","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luoting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,18]]},"reference":[{"key":"730_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"730_CR2","first-page":"1068","volume":"8","author":"IF Faneyte","year":"2002","unstructured":"Faneyte IF, Kristel PM, Maliepaard M et al (2002) Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 8:1068\u20131074","journal-title":"Clin Cancer Res"},{"key":"730_CR3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ejca.2003.09.036","volume":"40","author":"J Walker","year":"2004","unstructured":"Walker J, Martin C, Callaghan R (2004) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40:594\u2013605","journal-title":"Eur J Cancer"},{"key":"730_CR4","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1038\/sj.onc.1204887","volume":"20","author":"C Ruiz de Almodovar","year":"2001","unstructured":"Ruiz de Almodovar C, Ruiz-Ruiz C, Munoz-Pinedo C et al (2001) The differential sensitivity of Bcl-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bcl-2 protein levels. Oncogene 20:7128\u20137133","journal-title":"Oncogene"},{"key":"730_CR5","first-page":"1057","volume":"22","author":"MB Gariboldi","year":"2003","unstructured":"Gariboldi MB, Ravizza R, Riganti L et al (2003) Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int J Oncol 22:1057\u20131064","journal-title":"Int J Oncol"},{"key":"730_CR6","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/sj.onc.1207515","volume":"23","author":"Y Pommier","year":"2004","unstructured":"Pommier Y, Sordet O, Antony S et al (2004) Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23:2934\u20132949","journal-title":"Oncogene"},{"key":"730_CR7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/0306-3623(95)00108-5","volume":"26","author":"S Prost","year":"1995","unstructured":"Prost S (1995) Mechanisms of resistance to topoisomerases poisons. Gen Pharmacol 26:1673\u20131684","journal-title":"Gen Pharmacol"},{"key":"730_CR8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/14789450.1.4.493","volume":"1","author":"D Vimalachandran","year":"2004","unstructured":"Vimalachandran D, Costello E (2004) Proteomic technologies and their application to pancreatic cancer. Expert Rev Proteomics 1:493\u2013501","journal-title":"Expert Rev Proteomics"},{"key":"730_CR9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1074\/mcp.R500004-MCP200","volume":"4","author":"R Chen","year":"2005","unstructured":"Chen R, Pan S, Brentnall TA, Aebersold R (2005) Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 4:523\u2013533","journal-title":"Mol Cell Proteomics"},{"key":"730_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00432-008-0460-9","volume":"135","author":"YX Yang","year":"2009","unstructured":"Yang YX, Sun XF, Cheng AL et al (2009) Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol 135:181\u2013189","journal-title":"J Cancer Res Clin Oncol"},{"key":"730_CR11","first-page":"160","volume":"7","author":"YQ Shi","year":"2004","unstructured":"Shi YQ, Hu WH, Yin F et al (2004) Regulation of drug sensitivity of gastric cancer cells by human calcyclin-binding protein (CacyBP). Gastric Cancer 7:160\u2013166","journal-title":"Gastric Cancer"},{"key":"730_CR12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1053\/j.gastro.2005.08.001","volume":"129","author":"R Chen","year":"2005","unstructured":"Chen R, Yi EC, Donohoe S et al (2005) Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129:1187\u20131197","journal-title":"Gastroenterology"},{"key":"730_CR13","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1002\/pmic.200300466","volume":"3","author":"AR Shekouh","year":"2003","unstructured":"Shekouh AR, Thompson CC, Prime W et al (2003) Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3:1988\u20132001","journal-title":"Proteomics"},{"key":"730_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/omi.2009.0046","volume":"13","author":"F Zhu","year":"2009","unstructured":"Zhu F, Wang Y, Zeng S, Fu X, Wang L, Cao J (2009) Involvement of Annexin A1 in multidrug resistance of K562\/ADR cells identified by the proteomic study. OMICS 13:467\u2013476","journal-title":"OMICS"},{"key":"730_CR15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-007-0536-2","volume":"61","author":"A Tong","year":"2007","unstructured":"Tong A, Zhang H, Li Z et al (2007) Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 61:791\u2013802","journal-title":"Cancer Chemother Pharmacol"},{"key":"730_CR16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M Hockel","year":"2001","unstructured":"Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266\u2013276","journal-title":"J Natl Cancer Inst"},{"key":"730_CR17","first-page":"5863","volume":"59","author":"JM Brown","year":"1999","unstructured":"Brown JM (1999) The hypoxic cell: a target for selective cancer therapy\u2014eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863\u20135870","journal-title":"Cancer Res"},{"key":"730_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(03)00012-0","volume":"195","author":"SM Evans","year":"2003","unstructured":"Evans SM, Koch CJ (2003) Prognostic significance of tumor oxygenation in humans. Cancer Lett 195:1\u201316","journal-title":"Cancer Lett"},{"key":"730_CR19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/cncr.11246","volume":"97","author":"R Bos","year":"2003","unstructured":"Bos R, Groep PVD, Greijer AE et al (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573\u20131581","journal-title":"Cancer"},{"key":"730_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00689633","volume":"13","author":"BA Teicher","year":"1994","unstructured":"Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13:139\u2013168","journal-title":"Cancer Metastasis Rev"},{"key":"730_CR21","first-page":"6316","volume":"9","author":"PM Voorhees","year":"2003","unstructured":"Voorhees PM, Dees EC, O\u2019Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316\u20136325","journal-title":"Clin Cancer Res"},{"key":"730_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1054-3589(08)57003-7","volume":"57","author":"B Ruggeri","year":"2009","unstructured":"Ruggeri B, Miknyoczki S, Dorsey B et al (2009) The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. Adv Pharmacol 57:91\u2013135","journal-title":"Adv Pharmacol"},{"key":"730_CR23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ejca.2007.01.038","volume":"43","author":"A Milano","year":"2007","unstructured":"Milano A, Iaffaioli RV, Caponigro F (2007) The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 43:1125\u20131133","journal-title":"Eur J Cancer"},{"key":"730_CR24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349\u2013360","journal-title":"Nat Rev Cancer"},{"key":"730_CR25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1101\/gad.13.5.505","volume":"13","author":"T Maniatis","year":"1999","unstructured":"Maniatis T (1999) A ubiquitin ligase complex essential for the NF-kappaB, Wnt\/Wingless, and Hedgehog signaling pathways. Genes Dev 13:505\u2013510","journal-title":"Genes Dev"},{"key":"730_CR26","first-page":"1136","volume":"9","author":"MH Ma","year":"2003","unstructured":"Ma MH, Yang HH, Parker K et al (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136\u20131144","journal-title":"Clin Cancer Res"},{"key":"730_CR27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0898-6568(98)00063-1","volume":"11","author":"B Olofsson","year":"1999","unstructured":"Olofsson B (1999) Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 11:545\u2013554","journal-title":"Cell Signal"},{"key":"730_CR28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1006\/bbrc.1998.8253","volume":"245","author":"T Sasaki","year":"1998","unstructured":"Sasaki T, Takai Y (1998) The Rho small G protein family-Rho GDI system as a temporal and spatial determinant for cytoskeletal control. Biochem Biophys Res Commun 245:641\u2013645","journal-title":"Biochem Biophys Res Commun"},{"key":"730_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/jmbi.2000.4262","volume":"305","author":"AP Golovanov","year":"2001","unstructured":"Golovanov AP, Chuang TH, DerMardirossian C et al (2001) Structure\u2013activity relationships in flexible protein domains: regulation of rho GTPases by RhoGDI and D4 GDI. J Mol Biol 305:121\u2013135","journal-title":"J Mol Biol"},{"key":"730_CR30","first-page":"1321","volume":"5","author":"Y Fukumoto","year":"1990","unstructured":"Fukumoto Y, Kaibuchi K, Hori Y et al (1990) Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins. Oncogene 5:1321\u20131328","journal-title":"Oncogene"},{"key":"730_CR31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1515\/CCLM.2002.037","volume":"40","author":"J Poland","year":"2002","unstructured":"Poland J, Schadendorf D, Lage H et al (2002) Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med 40:221\u2013234","journal-title":"Clin Chem Lab Med"},{"key":"730_CR32","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1002\/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W","volume":"21","author":"P Sinha","year":"2000","unstructured":"Sinha P, Kohl S, Fischer J et al (2000) Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 21:3048\u20133057","journal-title":"Electrophoresis"},{"key":"730_CR33","first-page":"462","volume":"22","author":"M Takano","year":"2003","unstructured":"Takano M, Goto T, Sakamoto M et al (2003) Identification of paclitaxel-resistance related genes by differential display using cDNA microarray in ovarian cancer cell lines. Proc Am Soc Clin Oncol 22:462","journal-title":"Proc Am Soc Clin Oncol"},{"key":"730_CR34","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1158\/0008-5472.CAN-05-0175","volume":"65","author":"BL Zhang","year":"2005","unstructured":"Zhang BL, Zhang YQ, Dagher MC et al (2005) Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 65:6054\u20136062","journal-title":"Cancer Res"},{"key":"730_CR35","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1021\/pr900461c","volume":"8","author":"F Zhang","year":"2009","unstructured":"Zhang F, Zhang L, Zhang B et al (2009) Anxa2 plays a critical role in enhanced invasiveness of multidrug resistant human breast cancer cells. J Proteome Res 8:5041\u20135047","journal-title":"J Proteome Res"},{"key":"730_CR36","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/ijc.24587","volume":"125","author":"A Kim","year":"2009","unstructured":"Kim A, Enomoto T, Serada S et al (2009) Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 125:2316\u20132322","journal-title":"Int J Cancer"},{"key":"730_CR37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/1615-9861(200110)1:10<1233::AID-PROT1233>3.0.CO;2-2","volume":"1","author":"G H\u00fctter","year":"2001","unstructured":"H\u00fctter G, Sinha P (2001) Proteomics for studying cancer cells and the development of chemoresistance. Proteomics 1:1233\u20131248","journal-title":"Proteomics"},{"key":"730_CR38","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/elps.200305456","volume":"24","author":"P Sinha","year":"2003","unstructured":"Sinha P, Poland J, Kohl S et al (2003) Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 24:2386\u20132404","journal-title":"Electrophoresis"},{"key":"730_CR39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.bbapap.2008.04.014","volume":"1784","author":"L Murphy","year":"2008","unstructured":"Murphy L, Henry M, Meleady P, Clynes M, Keenan J (2008) Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochim Biophys Acta 1784:1184\u20131191","journal-title":"Biochim Biophys Acta"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-011-0730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-011-0730-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-011-0730-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T02:14:44Z","timestamp":1559355284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-011-0730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,18]]},"references-count":39,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s11010-011-0730-8","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,18]]}}}